– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with ...

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL). A study of 32 clinical samples from ...

The combination of glofitamab (Columvi) plus polatzumab vedotin (Polivy) demonstrated high efficacy and durable responses in patients with relapsed/refractory large B-cell lymphoma (LBCL), according ...

A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.

Monjuvi shows real-world effectiveness in relapsed/refractory DLBCL, with 11.3 months PFS and 24.8 months OS. Second-line Monjuvi treatment yields higher ORR (78.5%) compared to third-line (62.8%).

Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab The IELSG37 ...